 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | ZIMBABWE AIDS NETWORK |
| Street 1: | 30 ST PATRICKS ROAD |
| Street 2: | |
| City: | HARARE |
| Province: | MANICALAND |
| Post Code: | 263 |
| Country: | Zimbabwe |
| Phone: | 002634570604 |
| Organization Email: | tnyandoro@zimaidsnetwork.org |
| Web Site: | http://zimaidsnetwork.org |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Communities |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Patient Organization |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Vision A society in which communities prevent and manage HIV, TB and other Non-Communicable Diseases ensuring equity and quality in health services. Mission To strengthen community system to contribute to national HIV, TB, and other Non-Communicable Diseases responses ensuring that the right to health is realized through an inclusive credible and representative national network of HIV and Health programming organizations operate at all levels Our Objectives We believe in supporting HIV/AIDS and TB communities access to Maternal and Child health , Adolescent Sexual and Reproductive Health , maternal child health Rights through Demand creation and provision of quality community programmes in prevention, treatment , care and support. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Delivery of health services and care Engaging political leaders and ensuring inclusive leadership Funding, including innovative and optimized approach to funding TB Care Provision of drugs, diagnostics and commodities Research and Development Technical Assistance Working on Community, Rights and Gender (CRG) Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 51 - 99 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 26 - 50 |
| Number of volunteers who are directly involved with TB: | 51 - 99 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | sinozwelo resource centre |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Zimbabwe AIDS Network`s strength lies in numbers and diversity of membership, differently niched members who have sustainable regular interface with the communities. The coordinated members therefore provide a platform for which national results can easily be achieved with impact. The other pillars mainly capacity building, research and monitoring and evaluation ensures the much desired capacity for results. Advocacy issues are dealt with at every layer with only those for the next layer cascading upwards, from community to national level. The utilization of media interns in chapters ensures ZAN has antenna for the raw advocacy issues which are refined with evidence as issues grow bigger , the reason why at national level we have a development worker that boasts of years of experience as an advocate. So at the lower levels ZAN members bring and work on advocacy issues with the guidance of the regional coordinator and those that cannot be dealt with by the members will go to regional level, dealt with and those not solved will filter to National level. All other national advocacy issues such as the low paediatric ART coverage, the low national health budget (still below the Abuja Declaration), the freeze in human resource for health and all national civic issues will be pursued with the relevant authorities to ensure change. | |
Geographical Reach | |
| Which country is your headquarters located in: | Zimbabwe |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: Most poor countries have a large and growing private medical sector. Evidence suggests that a large proportion of tuberculosis patients in many high TB- burden countries first approach a private health care provider. Further, private providers manage a significant proportion of tuberculosis cases. Surprisingly though, there is virtually no published evidence on linking private providers to tuberculosis programmes. As a part of global efforts to control tuberculosis through effective DOTS implementation, the World Health Organization has recently begun addressing the issue of private providers in TB control through an evolving global strategy. As a first step, a global assessment of private providers' participation in tuberculosis programmes was undertaken. The findings of the assessment were discussed and debated in a consultation involving private practitioners, TB programme managers and policy makers. Their recommendations have contributed to the evolving global strategy called Public-Private Mix for DOTS implementation (PPM DOTS). This paper presents the guiding principles of PPM DOTS and major elements of the global strategy. These include: informed advocacy; setting-up "learning projects"; scaling-up successful projects and formulation of regional, national and local strategies; developing practical tools to facilitate PPM DOTS and pursuing an operational research agenda to help better design and shape PPM DOTS strategies. Encouraging results from some ongoing project sites are discussed. The paper concludes that concerted global efforts and local input are required for a sustained period to help achieve productive engagement of private practitioners in DOTS implementation. Such efforts have to be targeted as much towards national tuberculosis programmes as towards private providers and their associations. Continued apathy in this area could not only potentially delay achieving global targets for TB control but also undo, in the long run, the hard-earned achievements of National TB Programmes. Drug-Resistant TB: The treatment of drug resistant TB has always been more difficult than the treatment of drug susceptible TB. It has required the use of “second line” or reserve drugs that are more costly and cause more side effects. Also the drugs must be taken for up to two years. The following is the type of problem that patients taking the drugs were faced with. Not all patients with drug resistant TB are eligible for treatment with a shorter regimen. A shorter regimen is usually considered suitable for patients with rifampicin resistant or multi drug resistant TB who have not been previously treated with second line drugs and in whom resistance to fluoroquinolones and second line injectables has been excluded or is considered highly unlikely. There needs to be a careful selection of patients to be enrolled in any shorter regimen. There also needs to be effective patient support to enable full adherence to treatment. It is recommended that patients are tested for susceptibility or resistance to fluoroquinolones and to the second line injectable agents used in the regimen before starting on a shorter MDR-TB regimen. Patients with strains resistant to any of the two groups of medicines should be transferred to treatment with a conventional MDR-TB regimen. The availability of rapid and reliable TB tests can be very valuable in deciding within a few days which patients are eligible for shorter MDR TB regimens. It can also provide information about what modifications to conventional MDR-TB regimens are necessary based on the resistance detected. The Line Probe Assay test can be used as an initial direct test, rather than tests such as the culture test to detect resistance to fluoroquinolones and to the second line injectable drugs. In settings where laboratory capacity for drug susceptibility testing (DST) for fluoroquinolones and injectable agents is not yet available, treatment decisions need to be guided by the likelihood of resistance to these medicines. This needs to take into account the patient’s clinical history and recent surveillance data. TB-HIV: TB and HIV co-infection is when people have both HIV infection, and also either latent or active TB disease. When someone has both HIV and TB each disease speeds up the progress of the other. In addition to HIV infection speeding up the progression from latent to active TB, TB bacteria also accelerate the progress of HIV infection.1 HIV infection and infection with TB bacteria are though completely different infections. If you have HIV infection you will not get infected with TB bacteria unless you are in contact with someone who also is infected with TB bacteria. Although if you live in a country with a high prevalence of TB this may have happened without you realizing it. Similarly if you have TB you will not get infected with HIV unless you carry out an activity with someone who already has HIV infection, which results in you getting the virus HIV from them. TB also occurs earlier in the course of HIV infection than many other opportunistic infections. The risk of death in co-infected individuals is also twice that of HIV infected individuals without TB, even when CD4 cell count and antiretroviral therapy are taken into account. Laboratory Strengthening: Laboratories play a central role in TB control, surveillance, diagnosis, and care. Strong laboratory services allow providers to detect TB, monitor treatment, and document results. Strong laboratory services also allow technicians to detect different types of the disease, including pulmonary TB, extra-pulmonary TB, multidrug resistant TB, and extensively drug resistant TB. Research to enhance treatment also depends on the precision of laboratory data. Despite the crucial role of laboratory services in TB control, millions of people are unable to access reliable laboratory services due to scarcity of trained staff, insufficient supplies, inaccurate technical procedures, and inadequate quality assurance protocols. MSH works with partners to support national TB policy design and improve laboratory management. We also collaborate with ministries of health and national public health programs to strengthen TB control plans, policies, and standards. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | April 4, 2017 |
| Last updated: | April 6, 2017 |